Evidence map›Paper›PMID 31625523›Full record

ArticleIET nanobiotechnology2019

Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-

Jaleh Varshosaz, Erfaneh Ghassami, Abdollah Noorbakhsh, Mohsen Minaiyan, Ali Jahanian-Najafabadi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IET nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jaleh VarshosazDepartment of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran. varshosaz@pharm.mui.ac.ir.
Erfaneh GhassamiDepartment of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
Abdollah NoorbakhshDepartment of Nanotechnology Engineering, Faculty of Advanced Sciences and Technology, University of Isfahan, Isfahan, Iran.
Mohsen MinaiyanDepartment of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Ali Jahanian-NajafabadiDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor 2 (HER-2) is overexpressed in 20-30% of human breast cancers, associated with poor prognosis and tumour aggression. The aim of this study was the production of trastuzumab-targeted Ecoflex nanoparticles (NPs) loaded with docetaxel and in vitro evaluation of their cytotoxicity and cellular uptake. The NPs were manufactured by electrospraying and characterised regarding size, zeta potential, drug loading, and release behaviour. Then their cytotoxicity was evaluated by MTT assay against an HER-2-positive cell line, BT-474, and an HER-2-negative cell line, MDA-MB-468. The cellular uptake was studied by flow cytometry and fluorescent microscope. The particle size of NPs was in an appropriate range, with relatively high drug entrapment and acceptable release efficiency. The results showed no cytotoxicity for the polymer, but the significant increment of cytotoxicity was observed by treatment with docetaxel-loaded NPs in both HER-2-positive and HER-2-negative cell lines, in comparison with the free drug. The trastuzumab-targeted NPs also significantly enhanced cytotoxicity against BT-474 cells, compared with non-targeted NPs.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell Line, TumorCoated Materials, BiocompatibleDocetaxelDrug CarriersDrug CompoundingDrug Delivery SystemsDrug LiberationDrug Screening Assays, AntitumorElectroplatingFemaleHumansNanoconjugatesNanoparticlesParticle SizeAntineoplastic AgentsCoated Materials, BiocompatibleDocetaxelDrug CarriersecoflexNanoconjugatespoly(butylene adipate-co-butylene terephthalate)PolyestersTrastuzumab

Identifiers

PMID31625523
PMCPMC8676484
OpenAlexW2941275859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.